This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab (PDS) in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab
- Eye Disorder
- Diabetic Macular Edema
Active, not recruiting
- United States
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic Macular Edema (DME) when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W).
A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema (Pagoda)
- Age ≥18 years at time of signing Informed Consent Form
- Documented diagnosis of diabetes mellitus (Type 1 or Type 2)
- HbA1c level of ≤10% within 2 months prior to screening or at screening
- Macular thickening secondary to DME involving the center of the fovea with CST ≥325 um on SD-OCT at screening
- BCVA score of 78 to 25 letters (20/32 to 20/320 approximate Snellen equivalent)
- High-risk proliferative diabetic retinopathy
- Active intraocular inflammation (grade trace or above)
- Suspected or active ocular or periocular infection of either eye
- Uncontrolled ocular hypertension or glaucoma and any such condition the investigator determines may require a glaucoma-filtering surgery during a patient's participation in the study
- Cerebrovascular accident or myocardial infarction within 6 months prior to randomization
- Atrial fibrillation diagnosis or worsening within 6 months prior to randomization
- Uncontrolled blood pressure
For the latest version of this information please go to www.forpatients.roche.com